The clinical investigator is ultimately responsible for the safety of patients enrolled in clinical research as well as for a substantial portion of the overall conduct ofa clinical trial. The training of clinical investigators is a critical success factor in conductingquality sponsored clinical research leading to regulatory approval. DIA is globally recognized as the premier organization for information exchange regarding drug development. In that tradition, DIA is now poised to offer certification to clinical investigators. This is a natural extension of DlA' s primary mission of education and training in drug development, and is a response to growing requests to add an integrative and high-quality certification process to DIA' s existing offerings.
W H Y C E RTI FI CAT1 0 N ?
The training of physicians, pharmacists, and PhDs can normally accommodate only minimal exposure to course content on the conduct and management of clinical trials. A physician's academic and practical education focuses. appropriately, on clinical medicine, with little time remaining for training in clinical trial methodologies, regulations, administrative concerns, and fiscal and project management.
Clinical trials have become increasingly complex in design and conduct. With the push for trials to recruit more and more patients, the development of increasingly sophisticated and novel therapies, the use of new technologies to gather and report patient data, and the advent of increasing regulations, being able to remain current in this area of one's profession is as important as maintaining a knowledge base in a given medical discipline. Certification is an accepted process for assuring that minimum standards of education, training, and experience are met in most professions, certainly including most specialties within clinical medicine. Physicians who choose to conduct clinical research in academic centers are required, in the course of their postgraduate education and training, or as new faculty, to complete a continuing certification examination process to show their understanding of their role in the protection of subjects participating in sponsored research conducted in institutions receiving federal (NIH) research support. Only relatively recently have programs begun to address the needs of investigators who conduct industry-sponsored trials that meet FDA standards. Although NIHand FDA-focused clinical research share strong emphases on patienthubject protection, there are distinct differences in management, reporting, oversight, and funding that warrant dedicated training and certification to assure the highest quality. The upcoming DIA certification process addresses this need by health professionals participating in FDA-related trials.
Worldwide, traditionally independent national drug approval processes are undergoing increasing 'harmonization." Consistent, high-quality training of clinical investigators assumes increasing importance as we look globally to conduct clinical trials. Coupling investigator training and certification with an "information-based," established organization that operates on an international scale would seem to be a natural fit that promises to enhance efforts to improve the quality and reliability of clinical research conducted in widely differing locations throughout the world.
W H Y D I A ?
The DIA Clinical Investigator Certification Program was developed specifically for physicians, pharmacists, and PhDs to provide content and test knowledge in conducting clinical trials. Experts developed the program from the perspective that investigators are key to success in the clinical trial process and that certification would be a tangible, milestone achievement, linked to an ongoing process of continuing education. Indeed. DIA' s new commitment to investigator certification adds a significant next step to the education and training offerings given by the organization. Most programs provided by DIA carry some form of continuing education credits and, as an accredited provider of both continuing medical and pharmaceutical education, DIA adheres to the most rigorous quality requirements.
The DIA Clinical Investigator Certification Program consists of two components. The first is an educational component developed by the DIA Center for Career and Professional Development that consists of a completely self-paced course of study, so that an investigator can spend as much time as needed on each prescribed topic. The second section, offered by a new DIA unit, DIA Certification. Inc., is a test that covers the information contained in the course materials. Review courses and ekarning programs will complement these initial offerings.
One of DlA' s great fundamental strengths lies in its 'neutrality" with regard to afliliation and funding. thereby representing all components of the drug development process. Further, it maintains and cultivates global perspectives and responsibilities. Therefore, resulting programs and training may be expected to provide consistent objectivity, independence, and perspective.
WHAT IS THE BENEFIT?
In light of the human and monetary costs associated with clinical trials, and the pressing demand for time-ly new therapies, everything possible needs to be done to insure the successful completion of quality clinical studies. One might legitimately question whether a "certification process" will address these issues. If we consider the clinical investigator as an engine that powers the clinical investigation process. then it follows that we should try to optimize (and improve) that engine for the benefit of the overall process.
Certification will serve as a clear statement to sponsors of the quality of investigators who participate in their studies. The educational content provided through DIA certification will be available for review, so the scope of knowledge will be easily documented. Accordingly, certified investigators will be positioned favorably in considerations of qualified investigators to participate in studies of interest.
Universities, hospitals, and medical centers that employ investigators will be pleased to know that certification is now available for FDA-based clinical trials to complement the initiatives for NIH-based clinical research. This relieves each institution from having to "reinvent the wheel" for assuring minimal standards in the faculty and staff who participate in industry-sponsored trials.
There is also a precedent for insurance companies to offer coverage to those who complete special training at preferential pricing. The best defense against actionable events is education and training.
Ultimately, it is patients who will benefit from a clinical trial community that fully understands not only the science, but the management, of clinical trials in a manner that keeps the rights, safety, and well-being of patients as a top priority.
The unique experience and scale of DIA provide the capability and capacity to accommodate large numbers of participants, provide up-to-date information with state-of-the-art presentation and certification methods, and assure that the certification process will not only endure but improve over time. This is a process that is 'in synch" with the evolving needs of contemporary clinical research.
As DIA members and clinical researchers, we welcome the opportunity to work with DIA staff in moving DIA certification of clinical investigators forward. Please join us in this endeavor.
